For 30 years, the Clinique médicale l’Actuel, under the medical direction of Dr. Réjean Thomas, has been bringing together healthcare professionals, with a focus in virology, to learn from guest experts and discuss the most relevant clinical practice challenges facing them today.
Hepatitis C Treatment: The French Experience
With Dr. Réjean Thomas and Prof. Christophe Hézode
After clicking PLAY, click on the lower bar’s subtitles icon [CC] for english subtitles.
- HCV treatment in France: as little ribavirin as possible and disappearance of interferon
- Criteria for choosing an HCV treatment: efficacy, tolerance and simplicity
- HCV and compensated liver cirrhosis: two treatment choices, with or without ribavirin
- Test for HCV viral load: before treatment and 12 weeks after
This activity is supported
by an educational grant from:
Hepatitis C Treatment
Prof. Christophe Hézode provides a brief overview of the HCV treatments offered in France in recent years, and presents the combinations of molecules that are now considered standard treatment for hepatitis C. While the HCV epidemic in France is similar to what is happening in Canada, there is a difference in the genotypes found in each country.
Among the criteria for determining the choice of treatment in France, efficacy comes first – at least a 95% sustained virologic response – followed by tolerance and simplicity. Stressing that interferon cannot be prescribed in France, Prof. Hézode emphasizes the trend toward minimizing the prescription of ribavirin, for tolerance reasons. Ideally, the treatment should also be short, with the fewest pills possible.
Treatment strategies are constantly evolving, offering patients interesting personalized options, particularly based on the genotype of the virus and the severity of kidney disease.
Réjean Thomas, MD, Dhc
CEO – Founder
Clinique médicale l’Actuel: Centre of Excellence HIV–STI–Hepatitis
Affiliated with the Centre hospitalier de l’Université de Montréal (CHUM)
Christophe Hézode, MD, PhD
Department of Hepatology
Henri Mondor Hospital,
AND THE SUPPORT OF
ViroChannel has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Réjean Thomas, MD, Dhc has a financial interest/relationship or affiliation with:
Advisory Boards: AbbVie, Bristol-Myers Squibb Janssen, Gilead, Merck, ViiV Healthcare
Christophe Hézode, MD, PhD has a financial interest/relationship or affiliation with:
Abbvie, BMS, Gilead, Janssen, MSD
Disclosure of Unlabeled Use The faculty of this educational activity may include discussions of products that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses. No responsibility is taken for errors or omissions. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.